tiprankstipranks
Advertisement
Advertisement

CLRB Stock Latest News

Cellectar Biosciences publishes iopofosine I 131 dose-escalation study results
The FlyCellectar Biosciences publishes iopofosine I 131 dose-escalation study results
17d ago
CLRB
Cellectar Biosciences initiated with a Buy at Brookline
PremiumThe Fly
Cellectar Biosciences initiated with a Buy at Brookline
20d ago
CLRB
Cellectar Biosciences Shareholders Approve Key Governance Measures
PremiumCompany Announcements
Cellectar Biosciences Shareholders Approve Key Governance Measures
22d ago
8K
CLRB
Cellectar Biosciences Bets on Iopofosine Breakthrough
PremiumCompany Announcements
Cellectar Biosciences Bets on Iopofosine Breakthrough
2M ago
CLRB
Cellectar Biosciences files to sell 51.21M shares of common stock for holders
PremiumThe Fly
Cellectar Biosciences files to sell 51.21M shares of common stock for holders
2M ago
CLRB
Cellectar Biosciences Announces Board Changes and New Director
PremiumCompany AnnouncementsCellectar Biosciences Announces Board Changes and New Director
2M ago
8K
CLRB
Cellectar Biosciences assumed with a Buy at Ladenburg
Premium
The Fly
Cellectar Biosciences assumed with a Buy at Ladenburg
3M ago
CLRB
Cellectar Biosciences Signals Pivotal Turn in Earnings Call
Premium
Company Announcements
Cellectar Biosciences Signals Pivotal Turn in Earnings Call
3M ago
CLRB
Cellectar Biosciences reports Q1 EPS ($1.33), consensus ($1.88)
PremiumThe Fly
Cellectar Biosciences reports Q1 EPS ($1.33), consensus ($1.88)
3M ago
CLRB
CLRB Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
CLRB Upcoming Earnings Report: What to Expect?
3M ago
CLRB
Cellectar Raises $35M to Advance Phase 3 Trial
PremiumCompany Announcements
Cellectar Raises $35M to Advance Phase 3 Trial
3M ago
8K
CLRB
Cellectar Biosciences price target lowered to $11 from $14 at Roth Capital
PremiumThe Fly
Cellectar Biosciences price target lowered to $11 from $14 at Roth Capital
3M ago
CLRB
Cellectar Biosciences reports CLOVER WaM trial achieves primary endpoint
PremiumThe FlyCellectar Biosciences reports CLOVER WaM trial achieves primary endpoint
3M ago
CLRB
Cellectar Therapeutics: Advancing Targeted Radiotherapeutics with Clear Clinical Catalysts Supporting a Buy Rating and $10 Price Target
Premium
Ratings
Cellectar Therapeutics: Advancing Targeted Radiotherapeutics with Clear Clinical Catalysts Supporting a Buy Rating and $10 Price Target
4M ago
CLRB
Cellectar Biosciences enrolls first patient in CLR 121125 trial
Premium
The Fly
Cellectar Biosciences enrolls first patient in CLR 121125 trial
4M ago
CLRB
Cellectar Biosciences upgraded to Buy from Hold at Maxim
PremiumThe Fly
Cellectar Biosciences upgraded to Buy from Hold at Maxim
5M ago
CLRB
Cellectar Biosciences Charts Risky Path to Approvals
PremiumCompany Announcements
Cellectar Biosciences Charts Risky Path to Approvals
5M ago
CLRB
Cellectar Biosciences price target lowered to $14 from $18 at Roth Capital
PremiumThe Fly
Cellectar Biosciences price target lowered to $14 from $18 at Roth Capital
5M ago
CLRB
Cellectar Biosciences reports FY25 EPS ($8.35) vs ($41.89) last year
PremiumThe Fly
Cellectar Biosciences reports FY25 EPS ($8.35) vs ($41.89) last year
5M ago
CLRB
CLRB Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsCLRB Upcoming Earnings Report: What to Expect?
5M ago
CLRB
Five new option listings and fourteen option delistings on February 23rd
Premium
The Fly
Five new option listings and fourteen option delistings on February 23rd
5M ago
PHB
PIN
Cellectar Biosciences expands global intellectual property estate
Premium
The Fly
Cellectar Biosciences expands global intellectual property estate
5M ago
CLRB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >